Literature DB >> 32269076

Crystal structures of lysophospholipid-bound MHC class I molecules.

Yoko Shima1,2, Daisuke Morita3,2, Tatsuaki Mizutani1,2, Naoki Mori4, Bunzo Mikami5, Masahiko Sugita1,2.   

Abstract

Newly synthesized major histocompatibility complex (MHC) class I proteins are stabilized in the endoplasmic reticulum (ER) by binding 8-10-mer-long self-peptide antigens that are provided by transporter associated with antigen processing (TAP). These MHC class I:peptide complexes then exit the ER and reach the plasma membrane, serving to sustain the steady-state MHC class I expression on the cell surface. A novel subset of MHC class I molecules that preferentially bind lipid-containing ligands rather than conventional peptides was recently identified. The primate classical MHC class I allomorphs, Mamu-B*098 and Mamu-B*05104, are capable of binding the N-myristoylated 5-mer (C14-Gly-Gly-Ala-Ile-Ser) or 4-mer (C14-Gly-Gly-Ala-Ile) lipopeptides derived from the N-myristoylated SIV Nef protein, respectively, and of activating lipopeptide antigen-specific cytotoxic T lymphocytes. We herein demonstrate that Mamu-B*098 samples lysophosphatidylethanolamine and lysophosphatidylcholine containing up to a C20 fatty acid in the ER. The X-ray crystal structures of Mamu-B*098 and Mamu-B*05104 complexed with lysophospholipids at high resolution revealed that the B and D pockets in the antigen-binding grooves of these MHC class I molecules accommodate these lipids through a monoacylglycerol moiety. Consistent with the capacity to bind cellular lipid ligands, these two MHC class I molecules did not require TAP function for cell-surface expression. Collectively, these results indicate that peptide- and lipopeptide-presenting MHC class I subsets use distinct sources of endogenous ligands.
© 2020 Shima et al.

Entities:  

Keywords:  MHC class I; Mamu-B; adaptive immunity; antigen presentation; human immunodeficiency virus (HIV); lipopeptide; lysophospholipid; major histocompatibility complex (MHC); self-peptide; structural biology; transporter associated with antigen processing (TAP)

Mesh:

Substances:

Year:  2020        PMID: 32269076      PMCID: PMC7242709          DOI: 10.1074/jbc.RA119.011932

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

2.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Nature       Date:  1991-05-23       Impact factor: 49.962

3.  Identification and Structure of an MHC Class I-Encoded Protein with the Potential to Present N-Myristoylated 4-mer Peptides to T Cells.

Authors:  Yukie Yamamoto; Daisuke Morita; Yoko Shima; Akihiro Midorikawa; Tatsuaki Mizutani; Juri Suzuki; Naoki Mori; Takashi Shiina; Hidetoshi Inoko; Yoshimasa Tanaka; Bunzo Mikami; Masahiko Sugita
Journal:  J Immunol       Date:  2019-05-01       Impact factor: 5.422

4.  Molecular requirements for T cell recognition of N-myristoylated peptides derived from the simian immunodeficiency virus Nef protein.

Authors:  Daisuke Morita; Yukie Yamamoto; Juri Suzuki; Naoki Mori; Tatsuhiko Igarashi; Masahiko Sugita
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

Review 5.  Review of four major distinct types of human phospholipase A2.

Authors:  Alexis M Vasquez; Varnavas D Mouchlis; Edward A Dennis
Journal:  Adv Biol Regul       Date:  2017-10-23

6.  Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2.

Authors:  F Gotch; J Rothbard; K Howland; A Townsend; A McMichael
Journal:  Nature       Date:  1987 Apr 30-May 6       Impact factor: 49.962

7.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

8.  Crystal structure of the N-myristoylated lipopeptide-bound MHC class I complex.

Authors:  Daisuke Morita; Yukie Yamamoto; Tatsuaki Mizutani; Takeshi Ishikawa; Juri Suzuki; Tatsuhiko Igarashi; Naoki Mori; Takashi Shiina; Hidetoshi Inoko; Hiroaki Fujita; Kazuhiro Iwai; Yoshimasa Tanaka; Bunzo Mikami; Masahiko Sugita
Journal:  Nat Commun       Date:  2016-01-13       Impact factor: 14.919

9.  Calnexin retains unassembled major histocompatibility complex class I free heavy chains in the endoplasmic reticulum.

Authors:  S Rajagopalan; M B Brenner
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

10.  A novel self-lipid antigen targets human T cells against CD1c(+) leukemias.

Authors:  Marco Lepore; Claudia de Lalla; S Ramanjaneyulu Gundimeda; Heiko Gsellinger; Michela Consonni; Claudio Garavaglia; Sebastiano Sansano; Francesco Piccolo; Andrea Scelfo; Daniel Häussinger; Daniela Montagna; Franco Locatelli; Chiara Bonini; Attilio Bondanza; Alessandra Forcina; Zhiyuan Li; Guanghui Ni; Fabio Ciceri; Paul Jenö; Chengfeng Xia; Lucia Mori; Paolo Dellabona; Giulia Casorati; Gennaro De Libero
Journal:  J Exp Med       Date:  2014-06-16       Impact factor: 14.307

View more
  1 in total

1.  Opening opportunities for Kd determination and screening of MHC peptide complexes.

Authors:  Janine-Denise Kopicki; Ankur Saikia; Stephan Niebling; Christian Günther; Raghavendra Anjanappa; Maria Garcia-Alai; Sebastian Springer; Charlotte Uetrecht
Journal:  Commun Biol       Date:  2022-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.